Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
about
Rofecoxib for osteoarthritisNSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen SpeciesDisparities in surgery among patients with intractable epilepsy in a universal health systemNonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational StudiesCardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balanceCOX-2 chronologyRNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cellsCholinesterase inhibitors and hospitalization for bradycardia: a population-based studyNon-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case–time–control studyThe impact of NSAID treatment on cardiovascular risk - insight from Danish observational data.Measuring population health using personal health messages.Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran communityDifferences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studiesRepression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugsA cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospitalSafety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.Deprescribing in Frail Older People: A Randomised Controlled Trial.Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue.Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.Statin use associates with a lower incidence of acute kidney injury after major elective surgeryPreclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.Persistent nonmalignant pain management using nonsteroidal anti-inflammatory drugs in older patients and use of inappropriate adjuvant medications.Recognizing the Risks of Chronic Nonsteroidal Anti-Inflammatory Drug Use in Older Adults.Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study.Red cell distribution width and all-cause mortality in critically ill patients.Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population.Cardiovascular disease in kidney donors: matched cohort study.Unintentional Discontinuation of Chronic Medications for Seniors in Nursing Homes: Evaluation of a National Medication Reconciliation Accreditation Requirement Using a Population-Based Cohort Study.Emerging analgesics in cancer pain management.Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense.A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.Elevation of blood urea nitrogen is predictive of long-term mortality in critically ill patients independent of "normal" creatinine.Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methodsAdverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesicsCoxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.Cardiovascular risks of cyclooxygenase inhibition.Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
P2860
Q24244871-1332FACC-0776-45E8-9F1A-844DDB465CA1Q26784322-8FBFF167-0380-4C24-8335-1D48C451800FQ27348665-596A3123-9DBE-4BE3-98C1-9C201B27EFFBQ28079436-EE8EBBE0-7E4A-4DDD-A0B3-587AA8E2048CQ28191924-670DEF38-D8B1-4907-95D5-50C4714514F5Q28192719-9D259BBC-C5E0-420A-9ABD-4836FC3265DEQ28196666-CE7CBC30-764B-4985-8EF5-B660B20A1C4AQ28476190-74A2F896-65F7-4D90-99A8-D1D725CC03E6Q28969131-D46F7146-18D7-4F83-AF87-E741EC46A5FEQ30791071-9419191A-C1D1-4827-AC79-7F9548945A84Q33626647-7B39459E-05B1-4FF6-A792-511F18009C2DQ33906348-E66E366F-2EB6-419D-937F-6ACEAAFD0962Q33941101-D4695101-3AC4-413A-A965-26BC2D506FA1Q34161193-B8FFF0A4-D8CC-4E0D-9B61-63128A314088Q34234828-189E4C5A-8E08-4D0E-8ABC-DAEBC54D06BAQ34259503-0BBBDB3A-DB90-40DA-BB16-F932901919BAQ34474985-8C368DC7-05E5-467A-B6CC-0A47D25DDCC7Q34516940-1F0A4ABA-D411-4B7E-98FE-8467D5110E94Q34556489-D3813F50-75C6-4FC0-9A29-70993DB02D32Q34556831-AF2DF22E-5193-45D6-A041-B33F52A22F3DQ34870827-2682DE56-1FC0-4206-8AA0-0361EB776BFCQ35048654-0CFBC823-0800-4262-B6B8-AA8EFD55D288Q35057487-64871F86-EFC2-42FE-812E-C6AF7C676CF3Q35171694-23C0E8E8-E9C0-4281-9795-4555B25043EDQ35208686-A9C1F154-DFB1-4A65-A6B5-AA12690FF0D3Q35593191-6787592A-A9B3-4C2A-A9AD-E13B93CDCCE1Q35772571-F69B732A-DE7F-461A-BAAB-EBE7FB09706BQ35794899-0B5838B1-449B-4AB8-AD89-1299D14A16D8Q35858027-0375193B-CABB-433B-BA48-FDCCA61A9162Q36066043-BDF1E354-B7E1-4C72-89E0-7FC0D6FA8594Q36075305-108C3B48-0A07-4D38-B45D-7C7B364C095EQ36125455-86D48F4E-44F9-47D6-9414-F29B1AA6AF35Q36252394-E8C2D8D3-5DF8-4CA9-B30C-09DF7874712EQ36319337-09DE8EBF-4AD2-47F8-B832-07943B9E6A48Q36485541-DD206C6E-ED8A-44ED-9AE4-BEF3B0C4D240Q36486905-5DA53FF7-A095-45F0-84CB-ADFFB9132594Q36520638-07078CE0-E8CF-4835-A11F-4E046932D552Q36673018-436E1F24-947A-4786-B27B-19F88D84ED4BQ36716456-7EA2A322-6A62-442D-BD38-770D283E57E2Q36761358-992C2CF7-B621-45DA-BAEC-0FB9B8A80345
P2860
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Cyclo-oxygenase-2 inhibitors v ...... population-based cohort study.
@ast
Cyclo-oxygenase-2 inhibitors v ...... population-based cohort study.
@en
Cyclo-oxygenase-2 inhibitors v ...... population-based cohort study.
@nl
type
label
Cyclo-oxygenase-2 inhibitors v ...... population-based cohort study.
@ast
Cyclo-oxygenase-2 inhibitors v ...... population-based cohort study.
@en
Cyclo-oxygenase-2 inhibitors v ...... population-based cohort study.
@nl
prefLabel
Cyclo-oxygenase-2 inhibitors v ...... population-based cohort study.
@ast
Cyclo-oxygenase-2 inhibitors v ...... population-based cohort study.
@en
Cyclo-oxygenase-2 inhibitors v ...... population-based cohort study.
@nl
P2093
P50
P1433
P1476
Cyclo-oxygenase-2 inhibitors v ...... population-based cohort study.
@en
P2093
Andreas Laupacis
David N Juurlink
Douglas S Lee
Gary Naglie
Muhammad Mamdani
P304
P356
10.1016/S0140-6736(04)16299-5
P407
P577
2004-05-01T00:00:00Z